|
See related MabCampath infusion information |
|
|
|
Manufacturer |
Genzyme |
|
Distributor |
DKSH |
|
Contents |
Alemtuzumab |
|
Indications |
Chronic lymphocytic leukemia. |
|
Dosage |
IV infusion over 2 hr. Adult Administer in escalating doses during the 1st wk assuming that each dose is well tolerated: Day 1: 3 mg; day 2: 10 mg; day 3: 30 mg. Then 30 mg daily 3 times wkly on alternate days. Max: 12 wk. |
|
Contraindications |
Type I hypersensitivity or anaphylactic reactions to murine proteins. Active systemic infections, HIV, active secondary malignancies. Pregnancy & lactation. |
|
Special Precautions |
Reinstitute w/ gradual dose escalation if therapy is withheld for >7 days. Ischemic heart disease, angina, patient on antihypertensive medication. Premedication w/ steroids, antihistamines & analgesics required. Anti-infective prohylaxis is recommended. Monitor FBC & cardiac function (if previously treated w/ cardiotoxic agents). Discontinue if platelet <25,000/microlitre or absolute neutrophil count < 250/microlitre. Permanent discontinuation if autoimmune anemia or autoimmune thrombocytopenia appears. May impair ability to drive or operate machinery. |
|
Adverse Drug Reactions |
Sepsis, pneumonia, herpes simplex, granulocytopenia, thrombocytopenia, anemia, pancytopenia, anorexia, headache, hypotension, dyspnea, nausea & vomiting, diarrhea, pruritus, urticaria, rash, rigors, fever, fatigue, increased sweating, bronchospasm, hypoxia, syncope, pulmonary infiltrates, acute resp distress syndrome, resp arrest, MI, arrhythmias, acute cardiac insufficiency & cardiac arrest.
View ADR Monitoring Form |
|
Drug Interactions |
Avoid vaccination w/ live viral vaccines w/in 12 mth after therapy.
View more drug interactions with MabCampath |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
MabCampath infusion |
|
MabCampath 30 mg/1 mL x 1 x 3's |
|
|
|
Manufacturer: |
Genzyme |
|
Distributor: |
DKSH
|
|
|
|
